Mineralys Therapeutics, Inc. cotiza a 22.23 USD y tiene una capitalización bursátil de $2.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affecte…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-2.85 | — | $-0.47 |
| Estimado | $-0.54 | $-0.53 | $-0.53 | $-0.44 |
| Sorpresa | — | -437.7% | — | -6.8% |
| Métrica | MLYS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -23.9% | -40.4% | +16.5% |
| ROA | -23.4% | -32.0% | +8.6% |
| Current Ratio | 43.76 | 2.84 | +40.92 |
| Debt / Equity | — | 0.28 | — |